| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
2-Macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese
From the Department of Neurology (Drs. Sodeyama, Yamada, and Mizusawa), Tokyo Medical and Dental University; the Departments of Internal Medicine (Drs. Itoh and Otomo) and Pathology (Dr. Suematsu), Yokufukai Geriatric Hospital; and the Department of Neuropathology (Dr. Matsushita), Tokyo Institute of Psychiatry, Tokyo, Japan.
Address correspondence and reprint requests to Dr. Masahito Yamada, Department of Neurology, Kanazawa University School of Medicine, 13-1, Takara-machi, Kanazawa 920-8640, Japan.
BACKGROUND: 
2-Macroglobulin (A2M) forms the complex with amyloid ß-protein (Aß) and is associated with degradation of Aß. It has been reported that the A2M gene (A2M) exon 18 splice acceptor deletion polymorphism influences the development of AD, regardless of apolipoprotein E-
4 (APOE-4) status.
OBJECTIVE: To determine the effect of A2M polymorphism on the development of AD and AD-type neuropathologic changes.
METHODS: The authors examined the A2M and APOE genotypes, the densities of the senile plaques (SPs), SPs with dystrophic neurites (NPs), and neurofibrillary tangles (NFTs) in the brains of 62 postmortem-confirmed sporadic AD and 90 nondemented patients from an autopsy series of elderly Japanese subjects.
RESULTS: There was no association of the A2M polymorphism with AD, age at onset, or duration of illness in AD. The A2M polymorphism was not associated with the SPs, NPs, or NFTs in AD or nondemented patients. The results remained insignificant, even when the A2M genotype groups were divided into subgroups by APOE-4 status.
CONCLUSION: The A2M polymorphism does not affect the development of sporadic AD or formation of AD-type neuropathologic changes.
Key words: AD—Apolipoprotein E—Neuropathologic change—Risk factor—Japanese—2-Macroglobulin—Polymorphism—Senile plaque—Neurofibrillary tangle
This article has been cited by other articles:
|
|
 |
|
  A. J. Saunders, L. Bertram, K. Mullin, A. J. Sampson, K. Latifzai, S. Basu, J. Jones, D. Kinney, L. MacKenzie-Ingano, S. Yu, et al. Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin Hum. Mol. Genet., November 1, 2003; 12(21): 2765 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Neugroschl and K. L. Davis Biological Markers in Alzheimer Disease Am J Geriatr Psychiatry, December 1, 2002; 10(6): 660 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N SODEYAMA, T IWATA, K ISHIKAWA, H MIZUSAWA, M YAMADA, Y ITOH, E OTOMO, M MATSUSHITA, and Y KOMATSUZAKI Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile) J. Neurol. Neurosurg. Psychiatry, October 1, 2001; 71(4): 556 - 557. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hashimoto, H. Jiang, T. Niikura, Y. Ito, A. Hagiwara, K. Umezawa, Y. Abe, Y. Murayama, and I. Nishimoto Neuronal Apoptosis by Apolipoprotein E4 through Low-Density Lipoprotein Receptor-Related Protein and Heterotrimeric GTPases J. Neurosci., November 15, 2000; 20(22): 8401 - 8409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Koster, B. Dermaut, M. Cruts, J. J. Houwing-Duistermaat, G. Roks, J. Tol, A. Ott, A. Hofman, G. Munteanu, M. M. B. Breteler, et al. The {{alpha}}2-macroglobulin gene in AD: A population-based study and meta-analysis Neurology, September 12, 2000; 55(5): 678 - 684. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
